Actively Recruiting
Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
Led by Stanford University · Updated on 2026-04-24
70
Participants Needed
1
Research Sites
1050 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether subjects could be candidates for treatment studies.
CONDITIONS
Official Title
Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of recessive dystrophic epidermolysis bullosa (RDEB) by a local dermatologist
- 7 years of age or older
You will not qualify if you...
- Medical instability limiting ability to travel to Stanford University Medical Center
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Stanford University School of Medicine
Stanford, California, United States, 94305
Actively Recruiting
Research Team
I
Irene Bailey-Healy
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here